While Helicobacter pylori is now established as a pivotal factor in gastric carcinogenesis, its mechanisms of action and timing in the premalignant process are the subject of research. This project builds upon a recently completed 12-year randomized chemoprevention trial in a high-risk region of Colombia. A significantly greater regression of premalignant lesions was observed in study participants who were treated and were cleared of H. pylori infection. Upon completion of the trial, participants who had not been in the ant -H.pylori treatment arm were offered standard triple therapy. Quarterly contact has been maintained with trial participants, and this project now proposes to evaluate the long-term effectiveness of anti-H.py/or/treatment in an adult population in which the community prevalence of infection is greater than 90%. A cohort of children has been followed-up for 6 years, String tests to culture H. pylori and stool samples to extract DNA are obtained periodically.
The specific aims of the study are to: 1. Conduct endoscopy survey, gastric biopsies, and cultures at 18 and 20 years after intervention 2. Test biomarkers of progression of the precancerous process, mainly methylation of CpG islands 3. Genotype Helicobacter pylori at different ages and different stages in the precancerous process
This project provides information of the long term effects of treating patients with antibiotics to cure their infection with the bacterium Helicobacter pylori. The original treatment took place in 1992-1993. How effective the treatment was in preventing cancer development will be investigated.
|Garay, Jone; Piazuelo, M Blanca; Majumdar, Sumana et al. (2016) The homing receptor CD44 is involved in the progression of precancerous gastric lesions in patients infected with Helicobacter pylori and in development of mucous metaplasia in mice. Cancer Lett 371:90-8|
|Murray-Stewart, T; Sierra, J C; Piazuelo, M B et al. (2016) Epigenetic silencing of miR-124 prevents spermine oxidase regulation: implications for Helicobacter pylori-induced gastric cancer. Oncogene 35:5480-5488|
|Yang, Ines; Woltemate, Sabrina; Piazuelo, M Blanca et al. (2016) Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia. Sci Rep 6:18594|
|Sobota, Rafal S; Kodaman, Nuri; Mera, Robertino et al. (2016) Epigenetic and genetic variation in GATA5 is associated with gastric disease risk. Hum Genet 135:895-906|
|Esmail, Michael Y; Bacon, Rebecca; Swennes, Alton G et al. (2016) Helicobacter Species Identified in Captive Sooty Mangabeys (Cercocebus atys) with Metastatic Gastric Adenocarcinoma. Helicobacter 21:175-85|
|Camargo, M Constanza; Kim, Kyoung-Mee; Matsuo, Keitaro et al. (2016) Anti-Helicobacter pylori Antibody Profiles in Epstein-Barr virus (EBV)-Positive and EBV-Negative Gastric Cancer. Helicobacter 21:153-7|
|Dubeykovskaya, Zina; Si, Yiling; Chen, Xiaowei et al. (2016) Neural innervation stimulates splenic TFF2 to arrest myeloid cell expansion and cancer. Nat Commun 7:10517|
|Singh, Kshipra; Al-Greene, Nicole T; Verriere, Thomas G et al. (2016) The L-Arginine Transporter Solute Carrier Family 7 Member 2 Mediates the Immunopathogenesis of Attaching and Effacing Bacteria. PLoS Pathog 12:e1005984|
|Dixon, Beverly R E A; Radin, Jana N; Piazuelo, M Blanca et al. (2016) IL-17a and IL-22 Induce Expression of Antimicrobials in Gastrointestinal Epithelial Cells and May Contribute to Epithelial Cell Defense against Helicobacter pylori. PLoS One 11:e0148514|
|Hardbower, Dana M; Asim, Mohammad; Murray-Stewart, Tracy et al. (2016) Arginase 2 deletion leads to enhanced M1 macrophage activation and upregulated polyamine metabolism in response to Helicobacter pylori infection. Amino Acids :|
Showing the most recent 10 out of 240 publications